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Background and objective: Spinocerebellar ataxia 7 (SCA7) is characterised by cerebellar ataxia and
visual loss. The aim of the present study was to elucidate the magnetic resonance imaging (MRI) findings
characteristic of patients with SCA7.
Methods: Twenty patients with SCA (eight SCA3, three SCA6, and nine SCA7) and 20 control subjects
underwent an MRI-based volumetric analysis.
Results: The pontine volume in patients with SCA7 was decreased by a greater amount than in patients
with other types of SCA (p,0.01), whereas the cerebellar volume was not different from that in other types
of SCA (p.0.05). Pontine atrophy was a consistent finding in all patients with SCA7 regardless of the
degree of cerebellar atrophy or the severity or duration of illness. In contrast, cerebellar atrophy was not
found in those with a short duration of illness or mild ataxia, but became prominent as the severity and
duration of illness progressed.
Conclusions: Our study suggests that neurodegeneration is ongoing during the life of individuals with
SCA7, and that the primary pathology in these individuals involves the brainstem rather than the
cerebellum. In addition, pontine atrophy is a prominent, consistent finding in SCA7, and may help in
establishing the clinical diagnosis of SCA7.
S
pinocerebellar ataxia type 7 (SCA7) is a neurodegenera-
tive disorder caused by a CAG/polyglutamine repeat
expansion mutation in the gene encoding the ataxin 7
protein. This type of mutation is known to cause nine
inherited neurodegenerative disorders, Huntington’s disease
(HD), dentatorubral pallidoluysian atrophy (DRPLA), and
SCA 1, 2, 3, 4, 5, 6, and 7.1
SCAs form a heterogeneous group of dominantly inherited
disorders characterised by progressive ataxia that results
from degeneration of the cerebellum and its afferent and
efferent connections. Although cerebellar atrophy is a
consistent feature in most symptomatic SCA patients, the
involvement of extracerebellar structures varies with the type
of SCA. Multiregional brain hypometabolism has been
observed in SCA, even in SCA6,2 in which selective cerebellar
atrophy is consistently observed,3 suggesting that the brain
dysfunction associated with SCAs is not limited to the
cerebellum. However, the initial site of involvement in each
type of SCA remains unclear.
With the availability of magnetic resonance imaging
(MRI), it has become possible to study the brain morphology
in SCA in vivo. Previous MRI studies revealed significant
differences in the pattern and extent of the morphological
alterations with different SCA mutations. There is more
severe cerebellar and brainstem atrophy in SCA2 than in
SCA1 and SCA3,4 5 and there is relatively selective involve-
ment of the cerebellum in SCA6.3 MRI-based volumetric
analysis appears to be of particular importance because the
neuropathological abnormalities observed in postmortem
examinations may only reflect far advanced pathological
changes. To the best of our knowledge, MRI-based volu-
metric analysis of patients with SCA7 has not been carried
out previously.
This study elucidates the characteristic MRI findings of
SCA7 compared with other SCA types. We hypothesised that
a morphometric analysis of patients with SCA7 could reveal
the disease course in the early stage of cerebellar ataxia.
Therefore, we conducted a volumetric analysis of nine
genetically confirmed SCA7 patients, and compared the
findings with those of other SCA patients and normal control
subjects.
METHODS
We studied 20 patients manifesting progressive ataxia as the
main clinical finding: nine patients with SCA7 from six
families and 11 patients with other types of SCA (eight SCA3
and three SCA6). Informed consent was obtained from all
enrolled patients.
For the molecular genetic studies, previously published
primer sequences and conditions for the polymerase chain
reaction were used to quantify the trinucleotide repeats of
SCA 1, 2, 3, 6, 7, and DRPLA.6–11 We also screened the patients
who lacked an expanded pathological allele and had a
maternal inheritance pattern for known mutations associated
with mitochondrial encephalopathy with ragged red fibre
(MERRF), as described previously.12 13 We excluded patients
with a clinical diagnosis of possible or probable multisystem
atrophy following the consensus statement published by
Gilman et al14 and those with MERRF gene mutations.
Twenty age and sex matched control subjects with no
evidence of organic brain disease, such as migraine or tension
headache, were selected for determination of reference values
for morphometric analysis.
The neurological examination carried out had a specific
focus on certain clinical features of brainstem involvement
(pyramidal and extrapyramidal symptoms, voluntary and
involuntary slow saccades, and dysphagia), and severity of
ataxia. The results were graded as follows: I, walks without
help; II, walks with some help; III, needs help to walk; IV,
needs help to stand; V, bed-ridden.
The subjects were examined using 1.5-T MRI. MRI based
volumetric analysis was performed according to previously
Abbreviations: DRPLA, dentatorubral pallidoluysian atrophy; HD,
Huntington’s disease; MRI, magnetic resonance imaging; SCA,
spinocerebellar ataxia
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published methods.5 15 The axial and sagittal T1-weighted
magnetic data (repetition time, TR=500 ms; echo time,
TE=8 ms; slice thickness, 4 mm; gap, 1 mm) were processed
using a commercially available computer workstation (Scion
Image Beta 4.02; Scion Corp, Frederick, MD). Brain
segmentation was performed manually on all controls and
patients with SCA by a neuroradiologist who was blinded to
the clinical data. The pons was segmented first. The pontine
volume was calculated by summation and linear interpola-
tion of the segmented axial slices. All slices between the
inferior limit of segmentation, set at the lowest point of the
pons, and the superior point of the pons were measured.
The pons and cerebellum were separated by transecting the
cerebellar peduncles along the plane of their entrance into
the pons, namely at the shortest segment between the
anterior recess of the fourth ventricle and the junction
between the lateral border of the peduncles and the cerebellar
cortex. Using this technique, the peduncles were largely
excluded from the pontine volume. The cerebellar volume
was calculated by summation and linear interpolation of the
segmented sagittal slices. The pontine and cerebellar volumes
were computed by multiplying the measured area per slice by
the section thickness. Both volumes were normalised to the
total intracranial volume, measured in cross-section, to
reduce interindividual variation15 and are expressed as the
percentage of the respective total intracranial volume. Other
areas of the brain were not measured.
The differences between the groups were analysed using
the Kruskal–Wallis H-test with the Mann–Whitney U-test as
a post hoc analysis. The relationships between the various
clinical parameters and the pontine or cerebellar volume and
between the CAG repeat length and the pontine or cerebellar
volume were evaluated using a linear regression analysis for
the SCA7 patients. Probability values less than 0.05 were
accepted as significant.
RESULTS
Volumetric analysis was performed in nine SCA7 patients,
eight SCA3 patients, three SCA6 patients, and 20 control
subjects. There were no significant differences in the clinical
features (age, duration of illness, age at onset, and severity of
ataxia) of patients with SCA7 and those with other types of
SCA (p.0.05).
The clinical and volumetric data for the nine patients with
SCA7 are shown in table 1. All the patients showed the
typical pattern of autosomal dominant cerebellar ataxia and
exhibited visual loss with pigmentary retinopathy on
ophthalmoscopy. Extracerebellar symptoms, such as pyrami-
dal and extrapyramidal symptoms, voluntary and involuntary
slow saccades, and dysphagia, were found more frequently in
patients with severe pontine atrophy (r=0.722, p,0.05). Of
the extracerebellar symptoms, slowing of saccades was most
frequently observed (table 1). However, an increased number
of CAG repeats did not significantly influence the volume of
the cerebellum (r=0.256, p.0.05) or pons (r=0.024,
p.0.05).
Figure 1A shows the similarity in the degree of pontine
atrophy in patients with different severity of illness. The
degree of pontine atrophy in a patient (case 1, fig 1A, left)
with disease of 22 years duration and severe cerebellar
symptoms (wheelchair bound) was similar to that of a
patient (case 4, fig 1A, right) with disease of six years
duration and mild cerebellar symptoms (walks without help)
(pontine volume/total intracranial volume, 0.38% v 0.33%).
Figure 1(B, C) show the correlation between pontine or
cerebellar atrophy and the duration of illness or severity of
ataxia in the patients with SCA7. The degree of cerebellar
atrophy was significantly correlated with both the duration of
illness (r=0.664, p,0.05, fig 1B) and the severity of ataxia
(r=0.673, p,0.05, fig 1C). However, there was no significant
correlation between pontine atrophy and any clinical para-
meters measured—that is, duration of illness, age of onset, or
severity of ataxia (p.0.05 in all cases). Pontine atrophy was
consistently observed in all the patients with SCA7, including
those with minimal ataxia and illness of very short duration.
Conversely, cerebellar atrophy was not found in either of the
two patients with illness of short duration ((4 years) and in
two of the three patients with mild ataxia (walks without
help).
Figure 2 summarises the MRI findings of the 20 patients
with SCA and the 20 control subjects. The volumes of both
the cerebellum and pons differed between the patients with
SCA7 and control subjects (p,0.001 in both cases; 95%
confidence interval (CI) of the difference, 1.822 to 3.54 and
0.348 to 0.493, respectively) (fig 2A). Although the degree of
pontine atrophy correlated with the cerebellar atrophy
(r=0.884, p=0.004), pontine atrophy was the most con-
sistent MRI finding in SCA7, regardless of the presence or
absence of cerebellar atrophy (fig 2A).
The cerebellar volume did not differ between the patients
with SCA7 and those with other types of SCA (p=0.239)
(fig 2B). In contrast, compared with the patients with other
SCA types, the patients with SCA7 had significant pontine
atrophy (SCA3 v SCA7, p=0.002; SCA6 v SCA7, p=0.009).
DISCUSSION
Clinical implications of our findings
SCA7 is characterised by cerebellar ataxia and visual loss, and
some characteristic clinical features of molecularly confirmed
SCA7 have been reported previously.16 However, the diag-
nosis of SCA7 based on clinical assessment has limited
accuracy because there is marked variation in the age of
onset, initial symptoms, and associated signs.16 It has been
reported that decreased visual acuity and pigmentary
macular degeneration are not necessarily found in patients
with SCA716 and may be observed in other SCAs.17
In this respect, MRI may be helpful in revealing significant
differences in the pattern and extent of the morphological
alteration in SCA7 and other SCAs. In this study, we observed
severe pontine atrophy in the patients with SCA7; this was
much more prominent than in other types of SCA (SCA3 and
SCA6) and was consistently found in patients with varying
degrees of cerebellar atrophy and severity of illness. Pontine
atrophy has been reported in other SCAs, even in SCA6,18
although it is quite unexpected for such patients to have
pontine atrophy with their cerebellum spared, which we
found in our patients with SCA7. All patients with SCA7 may
not have the neuroradiological characteristics observed in
this study, yet pontine atrophy was a prominent finding in
our patients with SCA7. Our results suggest that assessment
of pontine involvement on MRI substantiates the clinical
diagnosis of SCA7. The difference between the ages of the
patients with SCA7, (mean 40.7 (SD 12.8) years), those with
other SCAs (37.9 (9.1) years), and normal control subjects
(40.4 (11.2) years) did not affect the baseline volumetric
data. The same was true for sex: SCA7 (male, 67%), other
SCAs (male, 45%), and normal control subjects (male, 50%).
In this study, both the pontine and cerebellar volumes
were normalised to the total intracranial volume, rather than
measuring each volume directly, because firstly, in degen-
erative diseases in which the whole brain is subject to
atrophy, the total intracranial volume may provide the best
available estimate of the premorbid brain volume, and
secondly, measuring the total intracranial volume allows
the whole brain and regional volumetric measures to be
normalised for head size. The pontine volumes of the female
control subjects included in this study were significantly
lower than those of the male control subjects (p=0.038), but
Pontine atrophy in SCA7 1453
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when we used this method of volumetric measurement,
neither the pontine nor the cerebellar volumes differed as
regards epidemiological factors such as age and sex.
Recently, Martin et al19 suggested that the term ‘‘mildly
affected patient’’ should be reserved for those who show a
definite degree of cerebellar atrophy without pontine
involvement on MRI. However, they used visual inspection
rather than volumetric analysis. In our volumetric analysis,
pontine atrophy was a consistent finding, and we did not find
a significant correlation between pontine atrophy and any of
the clinical parameters measured or the CAG repeat length.
Further studies with more subjects are needed to confirm
possible relationships between the clinical parameters or CAG
repeat length and the degree of pontine or cerebellar atrophy.
Table 1 Clinical and neuroimaging findings of nine patients with spinocerebellar ataxia 7
Case
No. of expanded
CAG repeats Sex/age
Age at the
onset of
symptoms
Duration of disease
in years (age at walking
aid)
Ataxia
scale
Extracerebellar
symptoms
Volume of the posterior fossa
structures/total intracranial
volume
Pons (%) Cerebellum (%)
1 45/10 F/59 37 22 (40) 5 Bulbar, EOM, PS 0.38 7.14
2 47/10 M/37 32 4 (self ambulatory) 1 EOM 0.63 10.47
3 43/10 F/52 39 13 (self ambulatory) 1 EOM, PS, EPS 0.35 8.30
4 47/10 M/40 34 6 (37) 2 Bulbar, EOM, PS, EPS 0.33 8.19
5 50/8 M/29 22 7 (self ambulatory) 1 EPS 0.38 7.80
6 46/10 M/33 29 4 (self ambulatory) 1 EOM, PS 0.61 11.22
7 44/12 M/59 45 14 (56) 3 Bulbar, EOM, PS, EPS 0.34 8.66
8 51/10 F/29 15 13 (22) 4 Bulbar, EOM, PS, EPS 0.31 7.27
9 NC M/28 19 9 (24) 5 EOM, PS 0.44 8.08
Bulbar, bulbar symptoms; EOM, extraocular movement disturbance; PS, pyramidal symptoms; EPS, extrapyramidal symptoms; NC, not checked
†
Figure 1 Correlation of clinical
parameters with pontine and cerebellar
volumes in nine patients with
spinocerebellar ataxia 7. (A) Similar
degree of pontine atrophy (0.38% v
0.33%) in patients with different severity
of illness: (left) patient with long
duration of disease and severe
cerebellar symptoms and (right) patient
with short duration of disease and mild
cerebellar symptoms. Correlation of
pontine and cerebellar volumes with (B)
the duration and (C) severity of illness.
*Inverse correlation of cerebellar
volume and the duration of illness.
Inverse correlation of cerebellar
volume and the severity of illness. The
grey area indicates the range of 2 SD
values of normal controls: cerebellum,
mean 11.14 (range of 2 SD 9.58–
12.70); pons, mean 0.84, (range of
2 SD 0.70–0.98).
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Neuropathological changes in patients with SCA7
The degenerative pattern may be specific enough to allow the
diagnosis of SCA on neuropathological grounds. Our volu-
metric data are in good agreement with the neuropatholo-
gical data of Martin et al,20 who found pontine atrophy to be a
prominent feature in patients with SCA7. A neuropathologi-
cal study of patients with SCA7, including a nearly
asymptomatic patient, showed involvement of the pyramidal
pathways and motor neurones of the brainstem and spinal
cord, in addition to cerebellar atrophy affecting both the
spinocerebellar and olivocerebellar tracts and the cerebellar
cortex and efferent cerebellar pathways.20
Using an ataxin 7 immunoreactivity test, Lindenberg et al21
recently reported that the intensity of staining differed from
region to region; staining was relatively strong in the inferior
olive, dentate nucleus, and pontine nuclei, whereas the
cerebellum, which was also affected, stained faintly.
Moreover, Holmberg et al22 found very few nuclear inclusions
in the cerebellum, a severely affected site in SCA7;
ubiquitinated nuclear inclusions, a common characteristic
in polyglutamine disorders, were frequently observed in the
brainstem (14–24%), but not in the cerebellum (,1%). Our
findings are in good agreement with this study in that
pontine involvement rather than cerebellar atrophy was a
consistent finding in SCA7. However, despite myriad studies
of ataxin 7 distribution in the brain and non-central nervous
system tissues of normal and SCA7 individuals, the distribu-
tion of ataxin 7 and the relation between ataxin 7 and
nuclear inclusions remain controversial.23
Distinct neuropathological pattern in SCA7
SCA2 also shows pontine atrophy that is complete quite early
during the course of SCA2; however, SCA2 differs from SCA7
in that it shows particularly widespread degeneration of
neuronal populations, including regions thought to be
typically affected in HD.24
Unlike SCA7 and SCA2, SCA6 displays predominant
Purkinje cell degeneration as the characteristic pathological
feature,25 and shows neuronal degeneration confined to the
cerebellar Purkinje cells and, to a lesser degree, the granular
cells, with no structural involvement of other parts of the
central nervous system.26 In the more common SCA3, the
neuropathological findings of autopsied brains include
neuronal cell loss in the dentate nucleus of the cerebellum,
pontine nuclei, substantia nigra, and inner segment of the
globus pallidus, and the preservation of the inferior olivary
nucleus and Purkinje cells of the cerebellar cortex.27 In a case
report, SCA3 showed a pattern consistently different from
SCA7, in that spinopontine involvement predominated over
cerebellar involvement, no olivary involvement was seen, and
the globus pallidus was clearly affected.28
Early involvement of the brainstem in patients with
SCA7
While SCA is diagnosed primarily from motor signs,
especially ataxia, a recent study suggests that other signs,
such as the slowing of saccades,29 precede motor disturbance
as cognitive deficits in HD.30 The slowing of saccades has been
reported to occur quite early in patients with SCA729 and
SCA2,31 suggesting that the brainstem regions that mediate
the generation of saccadic eye movements are a site of early
neurodegeneration in both SCA7 and SCA2. Patients with
SCA7 or SCA2 have been reported to show pontine
atrophy.4 32 In our study, the slowing of voluntary and
involuntary saccades was observed in eight of the nine
patients with SCA7, independent of the duration or severity
of illness.
Longitudinal studies using positron emission tomography
(PET) or brain single photon emission computed tomography
(SPECT) may help in understanding the timing and extent
of the changes in the brain in patients with SCA7.
Unfortunately, PET scanners are unavailable in most nuclear
medicine laboratories, and brain SPECT imaging may under-
estimate pons abnormalities because of technical problems
(the size of this structure and the resolution of the
scintillation camera). We therefore conducted a volumetric
analysis of patients with SCA7 of variable duration and
severity of illness. Our results suggest that cerebellar atrophy
is not found at the early symptomatic stage, but becomes
prominent as the severity and duration of illness progress. A
more important feature was that pontine atrophy was present
in all patients with SCA7, including those in the early
symptomatic stage. Our data for SCA7 contrast with the data
on SCA3, in which atrophy develops in both the brainstem
and cerebellum during the presymptomatic stage.33
Limitations of the study
This study has some limitations. First, we focused mainly on
the changes in the pons and cerebellum and did not measure
other intracranial structures. It should be mentioned that the
atrophy of other structures of the central nervous system,
such as the striatum, is reported to be a consistent
neuropathological feature in the early stages of SCA2 and
SCA3, but not in SCA7. Secondly, and most importantly, we
did not perform an MRI morphometric analysis of asympto-
matic gene carriers of SCA7. Until sufficient data from
Figure 2 Morphometric analysis of
spinocerebellar ataxias (SCAs):
correlation of pontine and cerebellar
volumes measured by volumetric
analysis. The volumes of both structures
are expressed as the percentage of the
respective total intracranial volume. (A)
The filled squares indicate the patients
with SCA7 and the filled diamonds the
control subjects; (B) the open squares
and the open diamonds indicate the
patients with SCA6 and SCA3,
respectively.
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presymptomatic patients are accumulated, it will remain
unresolved whether the disease progresses linearly from birth
or develops as a multistage process with a long latent period
followed by rapid progression of the dysfunctional stage.
Lastly, we did not compare SCA7 with other types of SCA in
which brainstem atrophy is reported to be a consistent
feature, such as SCA2.4
CONCLUSIONS
In summary, our results suggest that neurodegeneration
progresses continuously during the life of individuals with
SCA7 and that the primary pathology may involve the
brainstem, rather than the cerebellum. Although not all
patients with SCA7 may have the neuroradiological char-
acteristics observed in this study, pontine atrophy is a
prominent finding in SCA7 and validates the clinical
diagnosis of SCA7.
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